Dynamic Contrast Enhanced MRI (DCE-MRI) Assessment of the Vascular Changes Induced With Bevacizumab Alone and in Combination With Interferon-alpha in Patients With Advanced Renal Cell Carcinoma: a phase II, open labelled, randomised, multicentre trial.

Trial Profile

Dynamic Contrast Enhanced MRI (DCE-MRI) Assessment of the Vascular Changes Induced With Bevacizumab Alone and in Combination With Interferon-alpha in Patients With Advanced Renal Cell Carcinoma: a phase II, open labelled, randomised, multicentre trial.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Interferon alpha-2a
  • Indications Renal cancer
  • Focus Pharmacodynamics
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 28 Feb 2010 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials record.
    • 24 Apr 2009 Roche added as trial sponsor, East and North Hertfordshire NHS Trust as lead trial centre as reported by ISRCTN.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top